DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma
Latest Information Update: 20 Sep 2023
At a glance
- Drugs Ipilimumab/nivolumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Acronyms DANTE; DANTE
- 15 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Oct 2022 Recruitment end date changed from 13/08/2023 to 15/09/2023, according to ISRCTN: Current Controlled Trials.
- 14 Oct 2022 Planned End Date changed from 31 May 2027 to 15 Oct 2024.